Organisation paid for research Program year 2025 Source: CMS Open Payments

Whitman Walker Institute Inc

Neither a doctor nor a teaching hospital

Research payments

$1,613,835

226 payments

Through program year 2025, Whitman Walker Institute Inc is reported as receiving $1,613,835 in research payments, across 226 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $315,950 24
2024 Research $395,846 31
2023 Research $299,708 35
2022 Research $115,685 17
2021 Research $184,789 34
2020 Research $160,499 42
2019 Research $141,359 43

Breakdown

Who paid Research payments · program years 2019–2025
  1. ViiV Healthcare Company $904,832 75 payments
  2. Gilead Sciences, Inc. $577,460 133 payments
  3. GlaxoSmithKline, LLC. $61,405 14 payments
  4. Janssen Research & Development, LLC $60,075 2 payments
  5. Amgen Inc. $10,063 2 payments
Studies the money was for Research payments · program years 2019–2025
  1. Effectiveness-Implementation Hybrid Type 1 Study on Home-Delivered Cab $474,543 7 payments
  2. A Phase Iiib, Randomized, Multicenter, Parallel-Group, Non-Inferiority $135,531 17 payments
  3. A Phase III, Randomized, Multicenter, Parallel-Group, Non-Inferiority $74,788 11 payments
  4. A Phase 4, Randomized, Open-Label, Two-Arm Study Evaluating Implementa $67,247 8 payments
  5. A Phase 3B, Multicenter, Single-Arm, Open-Label Study Evaluating the E $61,405 14 payments
  6. A Multi Center Randomized double blind Placebo controlled Phase 3 Efficacy Study of a Heterologous Vaccine Regimen of Ad26.Mos4.HIV and Adjuvanted Clade C gp140 and Mosaic gp140 to Prevent HIV1 Infection Among Cisgender Men and Transgender Individuals who $60,075 2 payments
  7. PH 3 HIV Two-Year Non-Inferiority Compared to Standard of Care Safety/ $57,649 14 payments
  8. A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People >= 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection $34,667 1 payment
  9. A Phase 4, Randomized, Open-Label, Three-Arm Study to Evaluate Impleme $32,333 6 payments
  10. A Phase 3B, Multicenter, Single-Arm, Open-Label Study Evaluating the E $27,882 4 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record